Integra Lifesciences Holdings Corp (NASDAQ:IART) Given Consensus Rating of “Hold” by Brokerages

Integra Lifesciences Holdings Corp (NASDAQ:IART) has been given an average recommendation of “Hold” by the fifteen ratings firms that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $61.92.

Several research firms have recently weighed in on IART. Zacks Investment Research lowered shares of Integra Lifesciences from a “buy” rating to a “hold” rating and set a $56.00 target price on the stock. in a report on Thursday, June 20th. Oppenheimer upped their target price on shares of Integra Lifesciences from $65.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. BTIG Research set a $70.00 target price on shares of Integra Lifesciences and gave the stock a “buy” rating in a report on Wednesday, July 24th. ValuEngine lowered shares of Integra Lifesciences from a “hold” rating to a “sell” rating in a report on Thursday, August 1st. Finally, Royal Bank of Canada set a $66.00 target price on shares of Integra Lifesciences and gave the stock a “hold” rating in a report on Friday, July 26th.

In other Integra Lifesciences news, insider Lisa Evoli sold 2,380 shares of the stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $63.00, for a total transaction of $149,940.00. Following the sale, the insider now owns 2,588 shares of the company’s stock, valued at approximately $163,044. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Kenneth Burhop sold 6,656 shares of the stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $63.98, for a total transaction of $425,850.88. Following the sale, the vice president now directly owns 15,921 shares in the company, valued at approximately $1,018,625.58. The disclosure for this sale can be found here. In the last three months, insiders have sold 36,844 shares of company stock worth $2,085,117. Insiders own 4.50% of the company’s stock.

Large investors have recently modified their holdings of the business. Steward Partners Investment Advisory LLC bought a new stake in Integra Lifesciences during the 2nd quarter worth about $26,000. Quadrant Capital Group LLC grew its holdings in Integra Lifesciences by 223.0% during the 1st quarter. Quadrant Capital Group LLC now owns 646 shares of the life sciences company’s stock worth $34,000 after acquiring an additional 446 shares during the last quarter. BNP Paribas Arbitrage SA grew its holdings in Integra Lifesciences by 120.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,320 shares of the life sciences company’s stock worth $129,000 after acquiring an additional 1,266 shares during the last quarter. World Asset Management Inc bought a new stake in Integra Lifesciences during the 1st quarter worth about $217,000. Finally, Stanley Laman Group Ltd. bought a new stake in Integra Lifesciences during the 1st quarter worth about $223,000. 82.17% of the stock is currently owned by hedge funds and other institutional investors.

Integra Lifesciences stock traded up $0.14 on Tuesday, hitting $61.32. The company’s stock had a trading volume of 9,644 shares, compared to its average volume of 395,084. The stock has a market capitalization of $5.34 billion, a price-to-earnings ratio of 25.26, a P/E/G ratio of 1.96 and a beta of 1.09. The company has a current ratio of 2.76, a quick ratio of 1.82 and a debt-to-equity ratio of 0.99. The firm has a fifty day simple moving average of $56.46. Integra Lifesciences has a one year low of $42.14 and a one year high of $66.41.

Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, July 24th. The life sciences company reported $0.73 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.08. The firm had revenue of $383.60 million for the quarter, compared to analyst estimates of $373.29 million. Integra Lifesciences had a net margin of 6.76% and a return on equity of 16.30%. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.60 EPS. On average, analysts predict that Integra Lifesciences will post 2.73 EPS for the current fiscal year.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

See Also: What are no-load funds?

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.